Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01850758 · ClinicalTrials.gov registry record · NA

Regenexx™ SD Versus Exercise Therapy for ACL Tears

A NA study of Anterior Cruciate Ligament Tear, sponsored by Regenexx.

Completed
Registry status
NA
Development phase
50
Enrollment target
1
Study location

NCT01850758: Completed NA study of Anterior Cruciate Ligament Tear, sponsored by Regenexx.

NCT01850758 is a NA study of Anterior Cruciate Ligament Tear that has completed, run by Regenexx. The registered enrollment target is 50 participants, below the 226-participant average among 11 other Anterior Cruciate Ligament Tear trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01850758, a NA study of Anterior Cruciate Ligament Tear, has completed, sponsored by Regenexx.

COMPLETED
Registry status
NA
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

The primary objective of this study is to compare the improvement in subject-reported clinical outcomes for Regenexx SD vs. Exercise Therapy treatment of partial and complete, non-retracted knee ACL ligament tears, from baseline to 3 months, with continued evaluation of efficacy and durability up to 24 months. Secondary objectives include evaluation of MRI evidence of tendon repair; incidence of post-operative complications, adverse events, re-injections, and surgical intervention; change in pain score and use of pain medications.

Primary Outcome

The primary endpoint for this study is the difference between treatment groups in the within patient mean change from baseline to 3 months in IKDC scores.

Conditions Studied

Anterior Cruciate Ligament Tear

Interventions

  • PROCEDURE Regenexx SD
  • OTHER Exercise Therapy

Study Locations (1)

Colorado

  • Centeno-Schultz Clinic - Broomfield

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2013-05
Est. Completion 2022-03-08
Phase NA
Regenexx

13 total trials

What the finished NCT01850758 record still lists

NCT01850758 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 226-participant average among 11 other Anterior Cruciate Ligament Tear trials with a reported enrollment target (78% lower).

The record links to 1 condition, with Anterior Cruciate Ligament Tear appearing as the primary indexed condition, and to 2 interventions - of which Regenexx SD is the first listed.

NCT01850758 reports a single indexed study location in Colorado.

Frequently Asked Questions

What is clinical trial NCT01850758 about?

NCT01850758 is a clinical study titled "Regenexx™ SD Versus Exercise Therapy for ACL Tears". The primary objective of this study is to compare the improvement in subject-reported clinical outcomes for Regenexx SD vs. Exercise Therapy treatment of partial and complete, non-retracted knee ACL ligament tears, from baseline to 3 months, with continued evaluation of efficacy and durability up to...

What is the current status of trial NCT01850758?

This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2013-05. Estimated completion is 2022-03-08.

What conditions does trial NCT01850758 study?

This clinical trial studies the following conditions: Anterior Cruciate Ligament Tear.

What interventions are being tested in trial NCT01850758?

The interventions under investigation include: Regenexx SD (PROCEDURE), Exercise Therapy (OTHER).

Who is sponsoring clinical trial NCT01850758?

This trial is sponsored by Regenexx, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01850758 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Anterior Cruciate Ligament Tear

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01850758's enrollment target sits among peer trials

50 8th of 11 higher than 3 of 11 other Anterior Cruciate Ligament Tear trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Anterior Cruciate Ligament Tear trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01850758, the US trial registry maintained by the National Library of Medicine. NCT01850758 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.